This article is part of a Chronicle. See more from this Chronicle
Sean-Paul Brankin, Nov 12, 2008
One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of the industry, has been to question the need for the investigation. What is certain is that the Commission has set itself a challenging task. It has chosen to investigate a number of competition law issues that are likely to pose substantial legal and evidential difficulties. However, the sector, and originat
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.119.133.228
Please verify email or join us to access premium content!